Detection of ganciclovir resistance after valacyclovir-prophylaxis in renal transplant recipients with active cytomegalovirus infection

被引:29
|
作者
Alain, S
Hantz, S
Scieux, C
Karras, A
Mazeron, MC
Szelag, JC
Imbert, BM
Fillet, AM
Gouarin, S
Mengelle, C
de Wilde, A
Cogne, N
Champier, G
Rogez, S
Legendre, C
Denise, F
机构
[1] Teaching Hosp Dupuytren, Dept Bacteriol Virol Hyg, EA, Limoges, France
[2] Teaching Hosp St Louis, Dept Nephrol, Paris, France
[3] Teaching Hosp St Louis, Dept Bacteriol Virol, Paris, France
[4] Teaching Hosp Lariboisiere, Dept Bacteriol Virol, Paris, France
[5] Teaching Hosp Dupuytren, Dept Nephrol, Limoges, France
[6] Teaching Hosp, Dept Virol, Nantes, France
[7] Teaching Hosp Pitie Salpetriere, Dept Virol, Paris, France
[8] Teaching Hosp Caen, Caen, France
[9] Teaching Hosp Purpan, Dept Virol, Toulouse, France
[10] Teaching Hosp Lille, Dept Virol, Lille, France
关键词
human cytomegalovirus; ganciclovir resistance; valaciclovir transplantation;
D O I
10.1002/jmv.20127
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Whether valaciclovir(VCV) prophylaxis could be responsible for ganciclovir (GCV)-resistance of Human cytomegalovirus (HCMV) in transplantation has never been documented. A multicentric retrospective pilot study was undertaken to detect GCV-resistance through mutations within the UL97 gene in renal transplant recipients who experienced active HCMV infection and received valacyclovir prophylaxis. Twenty-three patients who experienced HCMV antigenaemia or DNAemia during or at the end of prophylaxis were included. UL97 genotyping was carried out on peripheral blood samples, using a nested in-house PCR, which amplified the full-length UL97 gene. One patient has a resistance-related mutation (M4601); the major risk factor for emergence of resistance in this patient was the presence of early and persistent antigenaemia. GCV-resistance during VCV-prophylaxis was rare after renal transplantation. However, special attention must be paid to patients developing early active HCMV infection under prophylaxis. (C) 2004 Wiley-Liss, Inc.
引用
收藏
页码:566 / 573
页数:8
相关论文
共 50 条
  • [41] Assay of cytomegalovirus susceptibility to ganciclovir in renal and heart transplant recipients
    Navarro, MD
    Melón, S
    Méndez, S
    Iglesias, B
    Palacio, A
    Bernardo, MJ
    Rodriguez-Lambert, JL
    Gómez, E
    TRANSPLANT INTERNATIONAL, 2002, 15 (11) : 570 - 573
  • [42] A simplified strategy for clinical management of late cytomegalovirus (CMV) infection after oral ganciclovir prophylaxis in renal recipients.
    Kuypers, DR
    Claes, K
    Evenepoel, P
    Maes, B
    Vanrenterghem, Y
    AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 168 - 168
  • [43] The emergence of cytomegalovirus resistance to ganciclovir therapy in kidney transplant recipients
    Nogueira, Eliana
    Ozaki, Kikumi S.
    Tomiyama, Helena
    Granato, Celso F. H.
    Camara, Niels O. S.
    Pacheco-Silva, Alvaro
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2006, 6 (13-14) : 2031 - 2037
  • [44] Cytomegalovirus infection resistant to ganciclovir in a renal transplant patient
    Valdez, O
    Gaspar, A
    Dickson, J
    Weigert, A
    Machado, D
    TRANSPLANTATION PROCEEDINGS, 2003, 35 (03) : 1081 - 1082
  • [45] COST-MINIMIZATION OF ORAL VALGANCICLOVIR VS INTRAVENOUS GANCICLOVIR FOR CYTOMEGALOVIRUS PROPHYLAXIS IN RENAL TRANSPLANT RECIPIENTS
    Alves Junior, J. M.
    Prota, F. E.
    Martinelli, J. C. B.
    Chrispim, A.
    Christoforo, F. F.
    Serpeloni, M.
    Barreto, I
    da Silva, A. C.
    VALUE IN HEALTH, 2024, 27 (06) : S85 - S85
  • [46] Role of antiviral prophylaxis in renal transplant recipients at high risk of cytomegalovirus infection
    Costa, Cristina
    Bergallo, Massimiliano
    Cavallo, Rossana
    JOURNAL OF CLINICAL VIROLOGY, 2008, 42 (03) : 293 - 294
  • [47] Superior cytomegalovirus prophylaxis with oral ganciclovir compared to oral acyclovir in pediatric renal, transplant recipients.
    Smith, L
    Somerville, T
    Sherbotie, J
    Shihab, F
    Holman, J
    TRANSPLANTATION, 2000, 69 (08) : S307 - S307
  • [48] Pharmacoeconomic Impact of Valganciclovir Versus Valacyclovir for Cytomegalovirus Prophylaxis in Renal Transplant Recipients: A Randomized Controlled Trial.
    Kacer, M.
    Kielberger, L.
    Bouda, M.
    Reischig, T.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 763 - 763
  • [49] Ganciclovir resistance of cytomegalovirus in lung transplant recipients: a case report
    Chanoine, Sebastien
    Hugon, Amelie
    Bedouch, Pierrick
    Germi, Raphaele
    Saint-Raymond, Christel
    Siyanko, Natalia
    Calop, Jean
    Allenet, Benoit
    Pison, Christophe
    PHARMACY WORLD & SCIENCE, 2010, 32 (02): : 296 - 296
  • [50] Pharmacoeconomic Impact of Valganciclovir Versus Valacyclovir for Cytomegalovirus Prophylaxis in Renal Transplant Recipients: A Randomized Controlled Trial.
    Kacer, M.
    Kielberger, L.
    Bouda, M.
    Reischig, T.
    TRANSPLANTATION, 2014, 98 : 763 - 763